Frugé Kristian S, Lee Young R
Clinical Pharmacist, Our Lady of the Lake Regional Medical Center, Baton Rouge, LA.
Assistant Professor of Pharmacy Practice, Texas Tech University of Health Sciences Center School of Pharmacy, Abilene, TX
Am J Health Syst Pharm. 2015 Sep 1;72(17 Suppl 2):S90-7. doi: 10.2146/sp150016.
To determine whether there is a difference between an activated partial thromboplastin time (aPTT) based unfractionated heparin (UFH) protocol versus an antifactor Xa based UFH protocol with respect to 24-hour attainment of therapeutic levels.
This was an observational study performed at a 500 bed private, community hospital. The study included inpatients from January 2008 to December 2009 on our institution's aPTT UFH protocol and inpatients from July 2010 to March 2011 on our institution's antifactor Xa UFH protocol. The two groups were compared to determine whether a higher percentage of patients reached therapeutic goal within 24 hours of UFH initiation. Secondary outcomes evaluated the percentage of patients at therapeutic goal within 6 and 12 hours, incidence of bleeding, and number of UFH dosage adjustments within 24 hours between the two groups.
One hundred twenty-one patients met inclusion criteria for this study; 79 in the aPTT group and 42 in the antifactor Xa group. At 24 hours, 74% of patients in the antifactor Xa group were at goal, versus 63% of patients in the aPTT group (p = 0.242). Nearly 57% of patients in the antifactor Xa group were at goal versus 27% in the aPTT group within 6 hours (p = 0.001). Subjects in the antifactor Xa group averaged 1.00 dosage adjustments per subject as compared to an 1.71 dosage adjustments per subject in the aPTT group within the first 24 hours (p = 0.003).
The antifactor Xa assay should be used to monitor UFH versus aPTT due to less variability in measurements, the absence of a need for calibration with new reagents/coagulometers, quicker attainment of therapeutic levels, fewer dose adjustments, and similar bleeding rates.
确定基于活化部分凝血活酶时间(aPTT)的普通肝素(UFH)方案与基于抗Xa因子的UFH方案在24小时内达到治疗水平方面是否存在差异。
这是一项在一家拥有500张床位的私立社区医院进行的观察性研究。该研究纳入了2008年1月至2009年12月采用本院aPTT UFH方案的住院患者以及2010年7月至2011年3月采用本院抗Xa因子UFH方案的住院患者。比较两组以确定在UFH开始使用后的24小时内达到治疗目标的患者百分比是否更高。次要结局评估两组在6小时和12小时内达到治疗目标的患者百分比、出血发生率以及24小时内UFH剂量调整次数。
121名患者符合本研究的纳入标准;aPTT组79例,抗Xa因子组42例。24小时时,抗Xa因子组74%的患者达到目标,而aPTT组为63%(p = 0.242)。6小时内,抗Xa因子组近57%的患者达到目标,而aPTT组为27%(p = 0.001)。抗Xa因子组患者在前24小时内平均每人调整剂量1.00次,而aPTT组为每人1.71次(p = 0.003)。
由于测量变异性较小、无需用新试剂/凝血仪进行校准、能更快达到治疗水平、剂量调整次数更少且出血率相似,应使用抗Xa因子测定法而非aPTT来监测UFH。